Dynavax Technologies Corp. [DVAX] stock is trading at $11.37, up 3.18%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The DVAX shares have gain 1.07% over the last week, with a monthly amount drifted -1.13%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Dynavax Technologies Corp. [NASDAQ: DVAX] stock has seen the most recent analyst activity on February 01, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $20. Previously, JMP Securities started tracking the stock with Mkt Outperform rating on September 27, 2022, and set its price target to $22. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $19 on August 06, 2021. H.C. Wainwright reiterated its recommendation of a Buy and reduced its price target to $12 on August 07, 2020. H.C. Wainwright reiterated a Buy rating for this stock on August 03, 2020, and upped its price target to $14. In a note dated June 15, 2020, Evercore ISI initiated an Outperform rating and provided a target price of $14 on this stock.
Dynavax Technologies Corp. [DVAX] stock has fluctuated between $10.48 and $15.15 over the past year. Currently, Wall Street analysts expect the stock to reach $20 within the next 12 months. Dynavax Technologies Corp. [NASDAQ: DVAX] shares were valued at $11.37 at the most recent close of the market. An investor can expect a potential return of 75.9% based on the average DVAX price forecast.
Analyzing the DVAX fundamentals
Dynavax Technologies Corp. [NASDAQ:DVAX] reported sales of 236.15M for the trailing twelve months, which represents a growth of 8.24%. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.02 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.05 points at the first support level, and at 10.72 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.57, and for the 2nd resistance point, it is at 11.77.
Ratios To Look Out For
For context, Dynavax Technologies Corp.’s Current Ratio is 15.20. Also, the Quick Ratio is 14.10, while the Cash Ratio stands at 2.36. Considering the valuation of this stock, the price to sales ratio is 6.30, the price to book ratio is 2.41 and price to earnings (TTM) ratio is 210.56.
Transactions by insiders
Recent insider trading involved CANO FRANCIS, Director, that happened on May 31 ’24 when 3615.0 shares were sold. Chief Accounting Officer, Burgess Justin completed a deal on Mar 01 ’24 to sell 20526.0 shares. Meanwhile, SVP and CMO Janssen Robert sold 1500.0 shares on Jan 04 ’24.
